ArticleNPJ vaccines2025
Cost-effectiveness of chikungunya vaccination with the live attenuated vaccine in U.S. territories.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A live attenuated chikungunya vaccine, IXCHIQ, was approved in the United States in 2023 for use in adults. We assessed the cost-effectiveness of two different vaccination strategies, routine and outbreak vaccination, for persons aged ≥18 years living in U.S. territories with previous transmission. We included the entire population of impacted U.S. territories and assumed one chikungunya outbreak occurring during a 30-year time horizon. We estimated that routine vaccination would avert 90% of the disease burden and cost $498 million (16% savings compared with no vaccination) while outbreak vaccination would avert 67% of the disease burden and cost $552 million (6% savings). Both strategies were more costly than no vaccination from the healthcare payer perspective. Routine vaccination was cost-saving for all outcomes assessed from a societal perspective. Outbreak vaccination was cost-saving for averted symptomatic cases but cost from $5 [95% CI: cost savings, $191] per chronic joint pain case averted to $373,054 [95% CI: $172,643, $573,464] per death averted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.